These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7927851)

  • 21. A population approach to the forecasting of amikacin plasma and urinary levels using a prescribed dosage regimen.
    Joubert P; Bressolle F; Gouby A; Douçot PY; Saissi G; Gomeni R
    Eur J Drug Metab Pharmacokinet; 1999; 24(1):39-46. PubMed ID: 10412890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice.
    Smits A; De Cock RF; Allegaert K; Vanhaesebrouck S; Danhof M; Knibbe CA
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6344-51. PubMed ID: 26248375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bayesian derived predictions for twice daily theophylline under outpatient conditions and an assessment of optimal sampling times.
    Chrystyn H; Ellis JW; Mulley BA; Peake MD
    Br J Clin Pharmacol; 1989 Feb; 27(2):215-21. PubMed ID: 2713215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Individualization of the amikacin administration regimen on the basis of the relationship between its pharmacokinetics and the patient's status].
    Firsov AA; Nasonov VN; Murav'eva SA; Portnoĭ IuA; Savitskaia KI
    Antibiot Khimioter; 1990 Sep; 35(9):47-51. PubMed ID: 2275595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Easy and practical utilization of CONSAM for simulation, analysis, and optimization of complex dosing regimens.
    Jackson AJ; Zech LA
    J Pharm Sci; 1991 Apr; 80(4):317-20. PubMed ID: 1865330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The design of oral sustained-release theophylline dosing after conversion from intravenous to oral therapy.
    Yamazaki M; Fukutomi O; Kondo N; Kato Z; Nakashima Y; Shinoda S; Agata H; Kondo T; Imaeda N; Orii T
    Int J Clin Pharmacol Ther; 1994 Nov; 32(11):625-31. PubMed ID: 7874380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amikacin population pharmacokinetics in critically ill Kuwaiti patients.
    Matar KM; Al-lanqawi Y; Abdul-Malek K; Jelliffe R
    Biomed Res Int; 2013; 2013():202818. PubMed ID: 23484093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Theophylline pharmacokinetics with concomitant steroid and gold therapy.
    Falcão AC; Rocha MJ; Almeida AM; Caramona MM
    J Clin Pharm Ther; 2000 Jun; 25(3):191-5. PubMed ID: 10886464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.
    Kato H; Hagihara M; Hirai J; Sakanashi D; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
    Drugs R D; 2017 Mar; 17(1):177-187. PubMed ID: 28063020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs. pharmacokinetic studies.
    el Desoky E; Meinshausen J; Bühl K; Engel G; Harings-Kaim A; Drewelow B; Klotz U
    Ther Drug Monit; 1993 Aug; 15(4):281-8. PubMed ID: 8236362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic dosing of aminoglycosides: a controlled trial.
    Bartal C; Danon A; Schlaeffer F; Reisenberg K; Alkan M; Smoliakov R; Sidi A; Almog Y
    Am J Med; 2003 Feb; 114(3):194-8. PubMed ID: 12637133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter quality control study of amikacin assay for monitoring once-daily dosing regimens. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Blaser J; König C; Fatio R; Follath F; Cometta A; Glauser M
    Ther Drug Monit; 1995 Apr; 17(2):133-6. PubMed ID: 7624900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin.
    Bachmann K; Jauregui L; Sides G; Sullivan TJ
    J Clin Pharmacol; 1993 Sep; 33(9):861-5. PubMed ID: 8227485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimation of once-daily amikacin dose in critically ill adults.
    Šíma M; Hartinger J; Cikánková T; Slanař O
    J Chemother; 2018 Feb; 30(1):37-43. PubMed ID: 28950787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen.
    Conil JM; Georges B; Breden A; Segonds C; Lavit M; Seguin T; Coley N; Samii K; Chabanon G; Houin G; Saivin S
    Int J Antimicrob Agents; 2006 Sep; 28(3):226-30. PubMed ID: 16908121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.
    Hermida J; Tutor JC
    Ther Drug Monit; 2006 Jun; 28(3):326-31. PubMed ID: 16778715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reliability of theophylline clearance in determining chronic oral dosage regimens.
    Slotfeldt ML; Johnson CE; Grambau G; Weg JG
    Am J Hosp Pharm; 1979 Jan; 36(1):66-8. PubMed ID: 758787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relative predictive performance of two theophylline pharmacokinetic dosing programs.
    Hoon TJ; Wood CA; Whidden MA; Greene WL; Bottorff MB
    Pharmacotherapy; 1988; 8(2):82-8. PubMed ID: 3399424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diurnal changes in the pharmacokinetic behavior of amikacin.
    Bleyzac N; Allard-Latour B; Laffont A; Mouret J; Jelliffe R; Maire P
    Ther Drug Monit; 2000 Jun; 22(3):307-12. PubMed ID: 10850398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amikacin once daily: a new dosing regimen based on drug pharmacokinetics.
    Maller R; Emanuelsson BM; Isaksson B; Nilsson L
    Scand J Infect Dis; 1990; 22(5):575-9. PubMed ID: 2259867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.